Cover Image
市場調查報告書

心房纖維顫動的中風預防 (SPAF)

Stroke prevention in atrial fibrillation

出版商 Datamonitor Healthcare 商品編碼 365168
出版日期 內容資訊 英文 158 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
心房纖維顫動的中風預防 (SPAF) Stroke prevention in atrial fibrillation
出版日期: 2016年03月01日 內容資訊: 英文 158 Pages
簡介

心房纖維顫動的中風預防 (SPAF)的市場規模,由於新的口服抗凝固藥 (NOAC)類的分子獲得拮抗劑的核準,以及醫生增加採用這些藥物,預計急速成長。

本報告以心房纖維顫動的中風預防 (SPAF) 為焦點,提供帶給SPAF的銷售額最大影響的患者亞群、市場,拮抗劑的認證帶給NOAC類採用的影響,SPAF的Savaysa的認證帶給市場動態的影響,瓣膜症性心房纖維顫動、非瓣膜症性心房纖維顫動雙方的發作預防之最常處方的治療藥,影響處方趨勢的最重要的要素等相關分析。

預測:心房纖維顫動的中風預防

  • 摘要整理
  • 市場概要、趨勢
  • 調查手法、市場定義
  • Eliquis (apixaban)
  • Pradaxa (dabigatran)
  • Savaysa (edoxaban)
  • Xarelto (rivaroxaban)
  • 1次調查手法

治療:心房纖維顫動的中風預防

  • 摘要整理
  • 1次調查手法
  • 疾病定義、診斷
  • 目前治療選擇
  • 處方趨勢

流行病學:心房纖維顫動

  • 摘要整理
  • 疾病的背景
  • 來源、手法
  • 預測
  • 流行病學者的考察
  • 能力與限制

上市藥:心房纖維顫動的中風預防

  • 摘要整理
  • 產品概要
  • 產品簡介:Eliquis
  • 產品簡介:Pradaxa
  • 產品簡介:Savaysa
  • 產品簡介:Xarelto

開發平台:心房纖維顫動的中風預防

  • 摘要整理
  • 開發平台趨勢

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC12571

The value of the stroke prevention in atrial fibrillation (SPAF) market is expected to grow rapidly as novel oral anticoagulant (NOAC) class molecules secure approvals of their antidotes and physician acceptance of these drugs rises.

This report addresses the following questions:

  • Which patient subgroups and markets will have the largest impact on SPAF sales?
  • How will the approval of antidotes affect uptake of the NOAC class?
  • Will Savaysa's recent approval for SPAF have a significant effect on the market dynamics?
  • What are the most commonly prescribed therapies for stroke prevention in both valvular and non-valvular atrial fibrillation patients?
  • What are the most important factors influencing prescribing trends?
  • How do prescribing trends correlate with current recommendations from clinical guidelines?

TABLE OF CONTENTS

FORECAST: STROKE PREVENTION IN ATRIAL FIBRILLATION

  • 1. Executive Summary
  • 2. Market Overview and Trends
  • 3. Market Definition and Methodology
  • 4. Eliquis (apixaban)
  • 5. Pradaxa (dabigatran)
  • 6. Savaysa (edoxaban)
  • 7. Xarelto (rivaroxaban)
  • 8. Primary Research Methodology

TREATMENT: STROKE PREVENTION IN ATRIAL FIBRILLATION

  • 9. Executive Summary
  • 10. Primary Research Methodology
  • 11. Disease Definition and Diagnosis
  • 12. Country Treatment Trees
  • 13. Current Treatment Options
  • 14. Prescribing Trends

EPIDEMIOLOGY: ATRIAL FIBRILLATION

  • 15. Executive Summary
  • 16. Disease Background
  • 17. Sources and Methodology
  • 18. Forecast
  • 19. Epidemiologist Insight
  • 20. Strengths and Limitations

MARKETED DRUGS: STROKE PREVENTION IN ATRIAL FIBRILLATION

  • 21. Executive Summary
  • 22. Product Overview
  • 23. Product profile: Eliquis
  • 24. Product profile: Pradaxa
  • 25. Product profile: Savaysa
  • 26. Product profile: Xarelto

PIPELINE: STROKE PREVENTION IN ATRIAL FIBRILLATION

  • 27. Executive Summary
  • 28. Pipeline Trends
Back to Top